212 related articles for article (PubMed ID: 18700192)
1. Hepatotoxicity in patients prescribed efavirenz or nevirapine.
Brück S; Witte S; Brust J; Schuster D; Mosthaf F; Procaccianti M; Rump JA; Klinker H; Petzold D; Hartmann M
Eur J Med Res; 2008 Jul; 13(7):343-8. PubMed ID: 18700192
[TBL] [Abstract][Full Text] [Related]
2. Hepatotoxicity associated with nevirapine or efavirenz-containing antiretroviral therapy: role of hepatitis C and B infections.
Sulkowski MS; Thomas DL; Mehta SH; Chaisson RE; Moore RD
Hepatology; 2002 Jan; 35(1):182-9. PubMed ID: 11786975
[TBL] [Abstract][Full Text] [Related]
3. Influence of liver fibrosis on highly active antiretroviral therapy-associated hepatotoxicity in patients with HIV and hepatitis C virus coinfection.
Aranzabal L; Casado JL; Moya J; Quereda C; Diz S; Moreno A; Moreno L; Antela A; Perez-Elias MJ; Dronda F; Marín A; Hernandez-Ranz F; Moreno A; Moreno S
Clin Infect Dis; 2005 Feb; 40(4):588-93. PubMed ID: 15712082
[TBL] [Abstract][Full Text] [Related]
4. Prospective, open-label comparative study of liver toxicity in an unselected population of HIV-infected patients treated for the first time with efavirenz or nevirapine.
Manfredi R; Calza L; Chiodo F
HIV Clin Trials; 2005; 6(6):302-11. PubMed ID: 16452064
[TBL] [Abstract][Full Text] [Related]
5. Hepatotoxicity in patients co-infected with tuberculosis and HIV-1 while receiving non-nucleoside reverse transcriptase inhibitor-based antiretroviral therapy and rifampicin-containing anti-tuberculosis regimen.
Mankhatitham W; Lueangniyomkul A; Manosuthi W
Southeast Asian J Trop Med Public Health; 2011 May; 42(3):651-8. PubMed ID: 21706943
[TBL] [Abstract][Full Text] [Related]
6. No increased risk of hepatotoxicity in long-term use of nonnucleoside reverse transcriptase inhibitors in HIV-infected patients.
Van Welzen B; Mudrikova T; Arends J; Hoepelman A
HIV Med; 2012 Aug; 13(7):448-52. PubMed ID: 22413955
[TBL] [Abstract][Full Text] [Related]
7. Are adverse events of nevirapine and efavirenz related to plasma concentrations?
Kappelhoff BS; van Leth F; Robinson PA; MacGregor TR; Baraldi E; Montella F; Uip DE; Thompson MA; Russell DB; Lange JM; Beijnen JH; Huitema AD;
Antivir Ther; 2005; 10(4):489-98. PubMed ID: 16038474
[TBL] [Abstract][Full Text] [Related]
8. Standard-dose efavirenz vs. standard-dose nevirapine in antiretroviral regimens among HIV-1 and tuberculosis co-infected patients who received rifampicin.
Manosuthi W; Mankatitham W; Lueangniyomkul A; Chimsuntorn S; Sungkanuparph S
HIV Med; 2008 May; 9(5):294-9. PubMed ID: 18400076
[TBL] [Abstract][Full Text] [Related]
9. Multicenter study of skin rashes and hepatotoxicity in antiretroviral-naïve HIV-positive patients receiving non-nucleoside reverse-transcriptase inhibitor plus nucleoside reverse-transcriptase inhibitors in Taiwan.
Wu PY; Cheng CY; Liu CE; Lee YC; Yang CJ; Tsai MS; Cheng SH; Lin SP; Lin DY; Wang NC; Lee YC; Sun HY; Tang HJ; Hung CC
PLoS One; 2017; 12(2):e0171596. PubMed ID: 28222098
[TBL] [Abstract][Full Text] [Related]
10. Concomitant use of nonnucleoside analogue reverse transcriptase inhibitors and rifampicin in TB/HIV type 1-coinfected patients.
Sathia L; Obiorah I; Taylor G; Kon O; O'Donoghue M; Gibbins S; Walsh J; Winston A
AIDS Res Hum Retroviruses; 2008 Jul; 24(7):897-901. PubMed ID: 18671475
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and tolerability of nevirapine- versus efavirenz-containing regimens in HIV-infected Thai children.
Lapphra K; Vanprapar N; Chearskul S; Phongsamart W; Chearskul P; Prasitsuebsai W; Chokephaibulkit K
Int J Infect Dis; 2008 Nov; 12(6):e33-8. PubMed ID: 18573672
[TBL] [Abstract][Full Text] [Related]
12. Efavirenz or nevirapine in three-drug combination therapy with two nucleoside-reverse transcriptase inhibitors for initial treatment of HIV infection in antiretroviral-naïve individuals.
Mbuagbaw LC; Irlam JH; Spaulding A; Rutherford GW; Siegfried N
Cochrane Database Syst Rev; 2010 Dec; (12):CD004246. PubMed ID: 21154355
[TBL] [Abstract][Full Text] [Related]
13. Analysis of severe hepatic events associated with nevirapine-containing regimens: CD4+ T-cell count and gender in hepatitis C seropositive and seronegative patients.
Torti C; Costarelli S; De Silvestri A; Quiros-Roldan E; Lapadula G; Cologni G; Paraninfo G; Castelnuovo F; Puoti M; Carosi G;
Drug Saf; 2007; 30(12):1161-9. PubMed ID: 18035868
[TBL] [Abstract][Full Text] [Related]
14. Hepatotoxicity in HIV-1-infected patients receiving nevirapine-containing antiretroviral therapy.
Martínez E; Blanco JL; Arnaiz JA; Pérez-Cuevas JB; Mocroft A; Cruceta A; Marcos MA; Milinkovic A; García-Viejo MA; Mallolas J; Carné X; Phillips A; Gatell JM
AIDS; 2001 Jul; 15(10):1261-8. PubMed ID: 11426070
[TBL] [Abstract][Full Text] [Related]
15. Liver toxicity of initial antiretroviral drug regimens including two nucleoside analogs plus one non-nucleoside analog or one ritonavir-boosted protease inhibitor in HIV/HCV-coinfected patients.
Macías J; Neukam K; Mallolas J; López-Cortés LF; Cartón JA; Domingo P; Moreno S; Iribarren JA; Clotet B; Crespo M; de Los Santos I; Ortega E; Knobel H; Jiménez-Expósito MJ; Pineda JA;
HIV Clin Trials; 2012; 13(2):61-9. PubMed ID: 22510353
[TBL] [Abstract][Full Text] [Related]
16. Nevirapine versus efavirenz based antiretroviral treatment in naive Indian patients: comparison of effectiveness in clinical cohort.
Patel AK; Pujari S; Patel K; Patel J; Shah N; Patel B; Gupte N
J Assoc Physicians India; 2006 Dec; 54():915-8. PubMed ID: 17334006
[TBL] [Abstract][Full Text] [Related]
17. Comparative durability of nevirapine versus efavirenz in first-line regimens during the first year of initiating antiretroviral therapy among Swaziland HIV-infected adults.
Takuva S; Evans D; Zuma K; Okello V; Louwagie G
Pan Afr Med J; 2013; 15():5. PubMed ID: 23847702
[TBL] [Abstract][Full Text] [Related]
18. Risk of tuberculosis after antiretroviral treatment initiation: a comparison between efavirenz and nevirapine using inverse probability weighting.
Hermans SM; Manabe YC; Kiragga AN; Hoepelman AI; Lange JM; van Leth F
Antivir Ther; 2013; 18(4):615-22. PubMed ID: 23423604
[TBL] [Abstract][Full Text] [Related]
19. Toxicity of non-nucleoside analogue reverse transcriptase inhibitors.
Kontorinis N; Dieterich DT
Semin Liver Dis; 2003 May; 23(2):173-82. PubMed ID: 12800070
[TBL] [Abstract][Full Text] [Related]
20. Incidence and risk factors for rash in Thai patients randomized to regimens with nevirapine, efavirenz or both drugs.
Ananworanich J; Moor Z; Siangphoe U; Chan J; Cardiello P; Duncombe C; Phanuphak P; Ruxrungtham K; Lange J; Cooper DA
AIDS; 2005 Jan; 19(2):185-92. PubMed ID: 15668544
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
